Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 51 Small Cell Lung Carcinoma 23 Breast Neoplasms 18 Sarcoma 17 Lung Neoplasms 10 Carcinoma, Hepatocellular 10 Esophageal Squamous Cell Carcinoma 9 Stomach Neoplasms 8 Neoplasms 8 Triple Negative Breast Neoplasms 7 Ovarian Neoplasms 7 Nasopharyngeal Carcinoma 7 Thyroid Neoplasms 6 Neoplasm Metastasis 6 Esophageal Neoplasms 6 Pancreatic Neoplasms 5 NSCLC 5 Colorectal Neoplasms 5 Carcinoma 5 Uterine Cervical Neoplasms 4 Pheochromocytoma 4 Endometrial Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Ovarian Epithelial 4 Recurrence 3 Paraganglioma 3 Non-squamous Non-small Cell Lung Cancer 3 Glioma 3 Fallopian Tube Neoplasms 3 Cholangiocarcinoma 3

Interventions

spartalizumab 1 sapropterin 1 penpulimab 1 niraparib 1 anlotinib 1 Taxes 1 Leucovorin 1 Ipilimumab 1 IFL protocol 1 Gemcitabine 1 Decitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Adenocarcinoma Metastatic × anlotinib × Clear all

NCT06051851 2023-09-25

RCT-PAAG

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡